Sign in Create account

Choksi Laboratories Ltd.

Healthcare · Healthcare Services

BSE: 526546
₹183.90
▼ -5.00 (-2.65%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
34/100
Weak
Valuation
36/100
Fairly Valued
Momentum
53/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹128 Cr
PE (TTM)
59.1
Industry median 50.2 (44 companies)
Price to Book
5.0
PEG (TTM)
1.3
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
196.1
Free Cash Flow
₹1 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
52.73%
as of June 30, 2026
Industry median 13.27% (57 companies)
Net Profit Growth (TTM)
95.90%
as of June 30, 2026
Industry median 7.21% (57 companies)
Operating Revenue Growth (TTM)
10.73%
as of June 30, 2026
Industry median 12.82% (57 companies)
Profit Growth (YoY)
51.17%
as of June 30, 2026
Industry median 8.53% (57 companies)
Revenue Growth (YoY)
7.30%
as of June 30, 2026
Industry median 18.84% (52 companies)
Current Ratio
0.82
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
1.18
as of March 31, 2026
Industry median 0.11 (62 companies)
Interest Coverage
2.07
as of June 30, 2026
Industry median 7.94 (57 companies)
Net Margin
4.82%
as of June 30, 2026
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
11.02%
as of June 30, 2026
Industry median 17.21% (61 companies)
Operating Margin (TTM)
13.05%
as of June 30, 2026
Industry median 16.20% (59 companies)
Return on Assets
3.39%
as of March 31, 2026
Industry median 5.40% (58 companies)
Return on Capital Employed
12.31%
as of March 31, 2026
Industry median 10.44% (56 companies)
Return on Equity
9.54%
as of March 31, 2026
Industry median 10.16% (58 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.18)
  • No Return on equity is 15% or more (9.5%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.6%
Low 179.5000 · High 188.0000
1W return
-6.8%
Low 178.7500 · High 205.0000
1M return
27.5%
Low 144.2500 · High 216.9500
52W return
193.3%
Low 110.5000 · High 216.9500
Lifetime High ₹209.9000 (Sept. 16, 2026)
Lifetime Low ₹5.2500 (March 22, 2014)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
188.5
10D
189.0
20D
180.4
50D
147.3
100D
116.9
200D
80.2

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
90.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

183.80
Pivot
First resistance188.10
Second resistance192.30
Third resistance196.60
First support179.60
Second support175.30
Third support171.10
Day RSI58.5
Day MFI81.7
Day MACD14.61
Day MACD signal18.56

Beta

1M-1.07
3M-0.98
1Y-0.98
3Y0.96

Price change analysis

↑ 27.5%
Over 1 Month
LowHigh
144.25216.95
↑ 193.3%
Over 3 Months
LowHigh
110.50216.95
↑ 193.3%
Over 6 Months
LowHigh
110.50216.95
↑ 193.3%
Over 1 Year
LowHigh
110.50216.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 59.1 (own history: 20.2–34.1)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹12 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.8400

Ranks #43 of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter31.48%
  • FII/FPI7.02%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 31.48% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 6.03% to 7.02% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 178 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
3 Sep 2026 EMKAY COMMERCIAL COMPANY LIMITED Bulk Buy 39,760 165.0000 BSE
31 Aug 2026 ASC CONSULTING PRIVATE LIMITED Bulk Sell 43,273 144.2500 BSE
31 Aug 2026 EMKAY COMMERCIAL COMPANY LIMITED Bulk Sell 118,000 144.2500 BSE
31 Aug 2026 NEXUS GLOBAL OPPORTUNITIES FUND Bulk Buy 161,273 144.2500 BSE
26 Aug 2026 M7 GLOBAL FUND PCC - CELL VERTEX Bulk Buy 40,000 145.6000 BSE
26 Aug 2026 EMKAY COMMERCIAL COMPANY LIMITED Bulk Sell 40,000 145.6000 BSE
19 May 2026 NEXUS GLOBAL OPPORTUNITIES FUND Bulk Buy 68,727 103.0500 BSE
19 May 2026 CSG FINANCIAL & MANAGEMENT SERVICES PRIVATE LIMITED Bulk Sell 70,000 103.0600 BSE
6 Nov 2025 ESSENCE DEALMARK PRIVATE LIMITED Bulk Sell 40,457 142.2800 BSE
13 Aug 2025 NEXUS GLOBAL OPPORTUNITIES FUND Bulk Buy 50,000 215.0000 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Choksi Analytical Services Ltd. to Choksi Laboratories Ltd.

All corporate actions →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Company Update Choksi Laboratories Ltd - 526546 - Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Sep 2026 AGM/EGM Choksi Laboratories Ltd - 526546 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
19 Sep 2026 Board Meeting Choksi Laboratories Ltd - 526546 - Board Meeting Outcome for Outcome Of Board Meeting Dated 19Th September, 2026
19 Sep 2026 Company Update Choksi Laboratories Ltd - 526546 - Announcement Under Regulation 30- Preferential Issue
18 Sep 2026 AGM/EGM Choksi Laboratories Ltd - 526546 - Shareholder Meeting / Postal Ballot-Outcome of AGM
14 Sep 2026 Board Meeting Choksi Laboratories Ltd - 526546 - Board Meeting Intimation for Board Meeting Dated 19.09.2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Low Return on Equity (9.5%)
  • Thin net profit margin (4.8%)
  • High financial leverage (Debt/Equity 1.18)
  • Tight liquidity (Current Ratio 0.82)

Opportunities

Data unavailable.

Threats

  • PE above 35 (59.1) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Choksi Laboratories Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.